About US
Contact us
-
UK research institutions and Nuevolution collaborate on cancer drug discoveryUK's Institute of Cancer Research (ICR) and Cancer Research Technology (CRT) have entered into a drug discovery collaboration with Denmark-based Nuevolution to identify novel lead candidates for treat2014/1/24
-
Santhera's Raxone gets French temporary approval for treatment of Leber's hereditary optic neuropathySwitzerland-based Santhera Pharmaceuticals has received 'Autorisation Temporaire d'Utilisation dite de cohorte' (cohort ATU), a temporary authorisation, from the French National Agency for Medicines a2014/1/23
-
Bladder Cancer Market to Witness Moderate Growth by 2017, Despite Anticipate​d Launch of EOquinThe bladder cancer therapeutics market in the six major countries (6MM) — the US, France, Germany, Italy, Spain and UK — is forecast to climb from $239.3 million in 2012 to $297.5 million by 2017, at2014/1/23
-
Aegerion's Juxtapid capsules approved for treatment of HoFH patients in MexicoThe Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has approved Aegerion Pharmaceuticals' Juxtapid (lomitapide) capsules for the treatment of homozygous familial hyperc2014/1/22
-
2D Barcode Scanner for Frozen SamplesMicronic, specialists in traceable sample storage solutions, has announced a further addition to its popular ‘blue-white’ Tracxer Code Reader line. The Tracxer Code Reader RD235 CRYO offers a high-2014/1/22
-
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic TestsHorizon Discovery Ltd, a leading provider of research tools to support translational genomics and the development of personalised medicines, and Transgenomic, Inc., a global biotechnology company adva2014/1/21
-
Mundipharma acquires rights to patents for heroin substitution from PhoenuxUK-based Mundipharma International has acquired exclusive global rights to a family of patents for heroin substitution, including a morphine/naloxone combination from Phoenux. In Europe about 1.4 mil2014/1/21
-
Gastrointe​stinal Therapeuti​cs Industry: Promising Drugs in Late-Stage Developmen​t Could Stabilise Declining Global MarketThe gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn’s disease (CD) in the eight major markets (8MM) — the US, UK, France, Germany, Ital2014/1/20
-
Zealand's partner Sanofi to start first Phase III study of LixiLan in Q1 2014Denmark-based Zealand Pharma has announced that the first LixiLan Phase III trial protocol has been approved, triggering a $15m payment from Sanofi. The payment was made by Sanofi under a licensing a2014/1/20
-
FDA accepts Iroko's Zorvolex sNDA for reviewThe US Food and Drug Administration (FDA) is to review Iroko Pharmaceuticals' supplemental new drug application (sNDA) for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug (NSAI2014/1/17